ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)

被引：0
|
作者：
Susanna Slater
Annette Bryant
Hsiang-Chi Chen
Ruwaida Begum
Isma Rana
Maria Aresu
Clare Peckitt
Oleg Zhitkov
Retchel Lazaro-Alcausi
Victoria Borja
Rachel Powell
David Lowery
Michael Hubank
Thereasa Rich
Gayathri Anandappa
Ian Chau
Naureen Starling
David Cunningham
机构：
[1] Royal Marsden Hospital NHS Foundation Trust,
[2] Biomedical Research Centre at the Royal Marsden and the Institute of Cancer Research,undefined
[3] Centre for Molecular Pathology at the The Royal Marsden Hospital and Institute of Cancer Research,undefined
[4] Guardant Health,undefined
[5] INC,undefined
来源：
BMC Cancer | / 23卷
关键词：
Colorectal cancer; ctDNA; Adjuvant chemotherapy; Randomised; Disease free survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] MEDOCC-CrEATE trial: Feasibility of measuring circulating tumor DNA after surgery to guide adjuvant chemotherapy in stage II colon cancer patients
    Franken, Ingrid
    Schraa, Suzanna
    van Rooijen, Karlijn
    van der Kruijssen, Dave
    Rubio-Alarcon, Carmen
    Ketelaars, Steven
    van Nassau, Sietske
    Snetselaar, Teunise
    Adriaans, Bregje
    Phallen, Jillian
    Angiuoli, Sam
    Greer, Amy
    Verner, Ellen
    Coupe, Veerle
    Verkooijen, Helena
    van Dongen, Miranda
    Bosch, Linda
    Lanfermeijer, Mirthe
    van den Broek, Daan
    Meijer, Gerrit
    Velculescu, Victor
    Sausen, Mark
    Koopman, Miriam
    Fijneman, Remond
    Vink, Geraldine
    CANCER RESEARCH, 2024, 84 (06)
  • [42] Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)
    Nakayama, Goro
    Takano, Nao
    Taniguchi, Hiroya
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Teramoto, Hitoshi
    Hashimoto, Ryoji
    Sakai, Mitsuru
    Ishiyama, Akiharu
    Kinoshita, Takashi
    Hayashi, Naomi
    Nakamura, Masanori
    Hattori, Norifumi
    Sato, Yusuke
    Umeda, Shinichi
    Uehara, Kei
    Aiba, Toshisada
    Sonohara, Fuminori
    Hayashi, Masamichi
    Kanda, Mitsuro
    Kobayashi, Daisuke
    Tanaka, Chie
    Yamada, Suguru
    Koike, Masahiko
    Fujiwara, Michitaka
    Murotani, Kenta
    Ando, Masahiko
    Ando, Yuichi
    Muro, Kei
    Kodera, Yasuhiro
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 61 - 71
  • [43] Current clinical practice of adjuvant chemotherapy for patients with 'high-risk' Stage II colorectal cancer in Japan: a questionnaire survey in the JCOG Study Group
    Ishiguro, Megumi
    Ueno, Hideki
    Kanemitsu, Yukihide
    Hamaguchi, Tetsuya
    Shida, Dai
    Shimada, Yasuhiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (12) : 1109 - 1112
  • [44] A phase III trial to confirm the superiority of S-1 adjuvant chemotherapy for vulnerable elderly patients with pathological stage II/III gastric cancer after curative resection: JCOG1507 (BIRDIE).
    Yamaguchi, Kazuya
    Yoshida, Kazuhiro
    Mizusawa, Junki
    Mizutani, Tomonori
    Ito, Seiji
    Nishida, Yasunori
    Yabusaki, Hiroshi
    Sano, Takeshi
    Sasako, Mitsuru
    Katayama, Hiroshi
    Fukuda, Haruhiko
    Boku, Narikazu
    Yoshikawa, Takaki
    Terashima, Masanori
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [45] High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy
    Zhou, Wenhao
    Yang, Fan
    Peng, Jianhong
    Wang, Fulong
    Lin, Yuzhu
    Jiang, Wu
    Yang, Xia
    Li, Liren
    Lu, Zhenhai
    Wan, Desen
    Pan, Zhizhong
    Fan, Wenhua
    JOURNAL OF CANCER, 2019, 10 (16): : 3810 - 3818
  • [46] Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial
    He, Yazhou
    Liu, Ping
    Zhang, Yuanchuan
    Deng, Xiangbing
    Meng, Wenjian
    Wei, Mingtian
    Yang, Tinghan
    Wang, Ziqiang
    Qiu, Meng
    TRIALS, 2015, 16
  • [47] Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial
    Yazhou He
    Ping Liu
    Yuanchuan Zhang
    Xiangbing Deng
    Wenjian Meng
    Mingtian Wei
    Tinghan Yang
    Ziqiang Wang
    Meng Qiu
    Trials, 16
  • [48] Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone
    Tsuji, T
    Sawai, T
    Takeshita, H
    Nakagoe, T
    Hidaka, S
    Nanashima, A
    Yamaguchi, H
    Yasutake, T
    Nagayasu, T
    Tagawa, Y
    CANCER LETTERS, 2004, 204 (01) : 97 - 104
  • [49] Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer (vol 39, pg 631, 2021)
    Iveson, Timothy J.
    Sobrero, Alberto F.
    Yoshino, Takayuki
    Souglakos, Ioannis
    Ou, Fang-Shu
    Meyers, Jeffrey P.
    Shi, Qian
    Grothey, Axel
    Saunders, Mark P.
    Labianca, Roberto
    Yamanaka, Takeharu
    Boukovinas, Ioannis
    Hollander, Niels H.
    Galli, Fabio
    Yamazaki, Kentaro
    Georgoulias, Vassilis
    Kerr, Rachel
    Oki, Eiji
    Lonardi, Sara
    Harkin, Andrea
    Rosati, Gerardo
    Paul, James
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15) : 1691 - 1691
  • [50] A randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX.
    Cartwright, Thomas H.
    Cohn, Allen Lee
    Richards, Donald A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345